Latest Trading Suspensions News

Metrics Income Opportunities Trust has released its audited FY2026 accounts, correcting the classification of valuation reductions while reporting an $18.2 million loss and a lower NTA. KPMG issued an unqualified opinion, but ASX has yet to determine when MOT units will resume trading and underlying funds remain closed to applications and redemptions.

xReality Group has identified unaudited adjustments that deepen its FY26 loss by $5.79 million and cut net assets from $14.0 million to $6.7 million. Customer revenue and cash flow are unchanged, but trading is suspended until the audit and amended accounts are completed.

Metrics Real Estate Multi-Strategy Fund units will remain suspended on ASX after the fund failed to lodge its audited financial statements. Reinstatement now depends on the accounts being filed and ASX deciding that trading can resume appropriately.

ASX will keep Metrics Master Income Trust securities suspended after the trust failed to lodge its audited financial statements. Trading will not resume until the accounts are filed and ASX considers reinstatement appropriate.

TerraCom’s securities will remain suspended from ASX quotation after the company failed to lodge its annual report for the year ended 30 June 2026. Reinstatement now depends on the report being filed and ASX considering it appropriate to resume trading.

ASX will keep xReality Group securities suspended after the company failed to lodge its revised Preliminary Final Report and audited financial statements. Trading cannot resume until those documents are filed and ASX considers reinstatement appropriate.

Chimeric Therapeutics remains suspended from ASX trading after failing to lodge its FY2026 financial statements, with the company reporting an approximate $7.7 million net asset deficiency and unresolved creditor negotiations. Potential recapitalisation interest has emerged, but no binding funding or settlement agreement has been reached.

ASX has suspended 15 listed companies from quotation after they failed to lodge required periodic reports by their deadlines. Trading may resume quickly if the outstanding reports are lodged, but the announcement gives no detail on the cause or length of each delay.

Patronus Resources enters FY2027 with approximately 2.3 million ounces of gold-equivalent Mineral Resources, $65.1 million in cash and liquid investments, and a 30,000-metre Northern Territory drilling campaign underway. The annual report also records an $8.6 million net loss and a proposed uranium rights transaction that remains conditional.

Metrics Income Opportunities Trust has been suspended from trading after its responsible entity warned that the audited FY2026 financial report may differ materially from figures released in August. The final report is expected on 30 September, but the filing does not disclose the size or direction of the changes.

Paradigm Biopharmaceuticals will keep its ASX securities suspended until at least 30 September while it reviews interim Phase 3 data and assesses the operational and financial consequences. The company also remains in discussions with Obsidian Global GP, LLC, but has not disclosed the trial results or their direction.

Nexsen has proposed a 50:50 joint venture with FlashDx Shenzhen to develop and commercialise an enhanced molecular Group B Streptococcus test, using an existing CE-marked platform as its starting point. The proposed venture could shorten Nexsen’s path into hospital and intrapartum testing across Asia-Pacific, but the term sheet remains non-binding and regulatory work is still ahead.